CJC-1295 + Ipamorelin: Growth Hormone Releasing Stack (2026 Update)

What it is: CJC-1295 (long-acting GHRH analog — sustained GH release) + Ipamorelin (selective GHRP — short pulses, minimal hunger/cortisol). Together they amplify natural pulsatile GH/IGF-1 without shutting down your axis like exogenous GH.

Evidence:

• Human studies (including 2006 CJC-1295 trial): Dose-dependent sustained GH (2–10x) and IGF-1 (1.5–3x) increases lasting days. Clear GH elevation but limited large RCTs on muscle/fat outcomes in healthy athletes.

• Athlete reports + smaller studies: Improved recovery, sleep, lean mass, fat loss, skin/joint health. Synergistic when combined (3–5x GH release vs Ipamorelin alone).

Athlete Benefits: Enhanced recovery, body recomp (muscle gain + fat loss), better sleep, energy, joint support. Good for older athletes or those with declining natural GH.

Typical Dosing:

• CJC-1295 (with DAC): 1–2 mg/week OR non-DAC 100 mcg 3x/day.

• Ipamorelin: 100–300 mcg 2–3x daily (often bedtime + post-workout).

• SubQ injections. Cycles: 8–12+ weeks; monitor IGF-1/glucose.

Side Effects: Water retention, transient insulin changes, possible carpal tunnel feelings at high doses. Generally well-tolerated; lower hunger than other GHRPs.

Sports Doc Note: Excellent for overnight recovery and recomp when diet/training are locked in. Get baseline + follow-up labs (IGF-1, fasting glucose, HbA1c). Not FDA-approved for performance.

Status (2026): Popular in wellness/performance clinics. Research-backed for GH elevation; real-world results vary.